SAN DIEGO, July 27, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. today announced that its Chief Executive Officer, Dr. Robert T. Foster, will discuss the company's hepatitis B development program for its lead antiviral drug, CPI-431-32, during a presentation at the Jefferies 2015 Hepatitis B Summit. The conference will take place on August 6th at the Boston Harbor Hotel.
Ciclofilin Presentation Details:
Date: Thursday, August 6th, 2015
Time: 9:30 a.m. Eastern Time
Location: Boston Harbor Hotel, North Atlantic Room
Ciclofilin is a privately held life sciences company based in San Diego, California, with R&D facilities in Edmonton, Canada. The company's lead drug, CPI-431-32, is uniquely designed to specifically target the host and not the virus. By targeting the host, CPI-431-32 interferes with the necessary cellular components that allow the virus to infect cells, replicate, and to propagate. CPI-431-32 has more than one mode of action; inhibition of viral transport into cells with additional downstream effects on the virus life cycle. In addition to the anti-HBV effects of CPI-431-32, cyclophilin inhibitors, as a class, may also target liver disease (liver inflammation and fibrosis, liver cirrhosis, and hepatocellular carcinoma).
CONTACT: Investor Contact Ciclofilin Pharmaceuticals, Inc., Dr. Robert T. Foster, CEO, +1 (780) 909-5041; Email: email@example.com Mr. Michael Kamdar, President, +1 (858) 733-1308; Email: firstname.lastname@example.org Media Contact Steve Kilmer, +1 (647) 872-4849; Email: email@example.comSource:Ciclofilin Pharmaceuticals Inc.